Skip to main content
Caplight Logo









Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

Public

Artelo Biosciences, Inc. is now publicly traded

The data on this page reflects Artelo Biosciences, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Seed Round

Mar 27, 2026

Total Funding Raised

$665,300

Company Overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting lipid-signaling pathways to treat cancer, pain, and other conditions.

AI Layer

Non-AI

Keywords

cancer-related anorexiacannabinoid receptor agonistclinical-stage biotechendocannabinoid systempharma cannabisdrug developmentlipid-signaling pathwayspharma licensingFABP5 inhibitorcancer anorexia-cachexia syndromeCACSneuropathic paincancer wastingchemotherapy-induced peripheral neuropathyCIPNCBD cocrystalcrypto on balance sheetSolana

Artelo Biosciences, Inc. Comparables

Compare Artelo Biosciences, Inc. with similar companies based on industry and business-model similarity.

Artelo Biosciences, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tensegrity Pharma, Inc.
63%
Receptor Life Sciences
57%
上海赛默罗生物科技有限公司
56%

Artelo Biosciences, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundMar 27, 2026
Seed RoundMar 27, 2026
Seed RoundMar 27, 2026

Artelo Biosciences, Inc. Filings

Explore SEC and related filing metadata, where available.

Artelo Biosciences, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

Headquarters—
Employee Range16
Year Founded2011
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?